

Professor MeiLan Han – The role of imaging in early COPD management

Select podcast references

- Ash SY, et al. *Radiol* 2021;299: <https://doi.org/10.1148/radiol.2021203531>. (CT progression and mortality)
- Buhl R, et al. *Adv Ther* 2020;37:4175–4189. (LAMA/LABA in treatment naïve patients with COPD)
- Chapman KR, et al. *Chest* 2001;119:1691–1695. (Gender bias in diagnosis of COPD)
- Couper D, et al. *Thorax* 2014;69:491–494. (SPIROMICS cohort)
- Decramer M, et al. *Lancet* 2009;374:1171–1178. (Subgroup analysis of UPLIFT study)
- Gold Initiative for Chronic Obstructive Lung Disease 2021. (LAMA/LABA in symptomatic patients)
- Han MK. *Int J Chron Obstruct Pulmon Dis* 2020;15:711–721. (COPD in women)
- Han MK, et al. *Am J Respir Crit Care Med* 2020;203:414–423. (From GOLD 0 to pre-COPD)
- Han MK, et al. *Chest* 2007;132:403–409. (Spirometry in COPD)
- Kesimer M, et al. *N Engl J Med* 2017;377:911–922. (Airway mucin levels in SPIROMICS cohort)
- Labaki WW & Han MK. *Ann Am Thorac Soc* 2018;15:S243–S248. (Detecting early COPD)
- Lange P, et al. *N Engl J Med* 2015;373:111–133. (Lung function trajectories leading to COPD)
- Lowe KE, et al. *Chronic Obstruct Pulmon Dis* 2019;6:384–399. (COPDGene® cohort)
- Maltais F, et al. *Chest* 2018;153:1315–1325. (Beta blocker interactions with LAMA/LABA)
- Mets OM, et al. *JAMA* 2011;306:1775–1781. (Identifying COPD with lung cancer screening CT scans)
- Rasmussen DB, et al. *Thorax* 2020;75:928–933. (Beta blocker use in COPD after myocardial infarction)
- Regan EA, et al. *JAMA* 2015;175:1539–1549. (Patients with normal spirometry)
- Wan ES, et al. *Am J Respir Crit Care Med* 2018;198:1397–1405. (PRISm COPDGene® study)
- Woodruff PG, et al. *N Engl J Med* 2016;374:1811–1821. (Smokers with preserved pulmonary function)
- Zhou Y, et al. *N Engl J Med* 2017;377:923–935. (Bronchodilation in early stage COPD)